STOCKHOLM - Medivir AB  Nasdaq Stockholm  MVIR , a Swedish pharmaceutical company, announced significant clinical advancements for its cancer drug fostrox in combination with Lenvima  in treating advanced hepatocellular carcinoma  HCC . Annually, around 660,000 people are diagnosed with primary liver cancer globally, with a five-year survival rate of less than 20 .This article is based on a press release statement from Medivir AB.This article was generated with the support of AI and reviewed by an editor.
Medivir AB's cancer drug fostrox, in combination with Lenvima, has shown promising clinical advancements in treating advanced hepatocellular carcinoma (HCC), a type of liver cancer with a low survival rate.